WO1994013789A2 - Oligonucleotides with rna cleavage activity - Google Patents
Oligonucleotides with rna cleavage activity Download PDFInfo
- Publication number
- WO1994013789A2 WO1994013789A2 PCT/GB1993/002486 GB9302486W WO9413789A2 WO 1994013789 A2 WO1994013789 A2 WO 1994013789A2 GB 9302486 W GB9302486 W GB 9302486W WO 9413789 A2 WO9413789 A2 WO 9413789A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oligonucleotide
- substituted
- diol
- formula
- sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3183—Diol linkers, e.g. glycols or propanediols
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
Definitions
- the present invention relates to oligonucleotides with RNA cleavage activity.
- RNA is known to have endoribonuclease activity
- Catalytic RNA molecules called ribozymes have been used to bind to target RNA molecules and catalyse their cleavage, thus blocking tne activity of the target RNA.
- the so-called hammerhead ribozymes have been widely studied.
- the recognition site and catalytic site of these oligoribonucleotides are well characterised and ricozymes containing a recognition sequence specific for any desired target RNA which contains a specified triplet can be constructed. These compounds can therefore ne considered as potential therapeutic agents with possibly higher biological activity than the simple antisense oligonucleotides (1) .
- FIG. 1 The structure of a typical hammerhead ribozyme is shown in Figure 1.
- a G C and U are all ribonucleotides.
- the hammernead ribozyme has been shown to have no effect in prokaryotic cells wnen the ribozyme and target RNA were generated from different genes, whereas it can function at a 1:1 ribozyme target ratio if co-localization in the same cell is maintained.
- Studies (1) have shown that a high (1000:1) ribozyme:sunstrate ratio is needed for inhibition in vivo in eukaryot ic cells . This suggests that the catalytic potential of the ribozyme is not being achieved.
- Eckstein et al introduced 2'-ammo or 2'-F substituents into the pyrimidine positions of the hammerhead ribozyme (2) (3) .
- the cleavage positions of the rioozymes in cellular extracts were not determined but the all-pyrimidme substitutions together with phosphorothiolate substitutions at the 3' terminus gave compounds with a markedly increased stability. The influence of these chemical modifications on the catalytic activity of the ribozymes was negligible.
- Cedergreen et al found that mixed DNA / RNA oligomers with 4-7 noopositions are active in cleaving substrate RNA. These oligomers are three orders of magnitude more stable than the all -RNA ribozymes in incubation with RNase A and yeast extract.
- McLaughlin et al (10 ) proposed a role for the 2'-OH as of G 5 or G 8 . They interact with H 2 O molecules bound in the first co-ordination sphere of the Mg 2+ cofactor.
- the present invention provides in a first aspect oligonucleotides having the following sequence 3' 5 '
- A is deoxyadenosine
- G is deoxvguanosine
- a is 2' substituted deoxyadenosine according to formula la below, or a 2' substituted arabinofuranosyl adenosine according to formula Ic below, or adenosine g is 2' substituted deoxvguanosine according to formula lb below or a 2' substituted arabinofuranosyl guanosine according to formula Id below, or guanosine
- R 1 being -H, -C(O)OH, or -CH 2 -C(O)OH
- oligonucleotide is other than adenosine or guanosine respectively;
- P is either a) A-U or b) C-G
- W is either i) nucleotide loop sequence IIa if P is A-U;
- each diol bridge (Z) is of formula IV
- n 1-10
- n may be independently selected for each bridge from l to 10.
- n is 3 in each bridge and there are four bridges;
- m is 4.
- X and Y are target specific recognition sequences made up of any deoxyribonucleosides N depending on the target RNA sequence.
- X and Y may be of the same or different length. There is no need for the molecule to be symmetrical. Each may be 4 to 25 nucleotides long, preferably 6 to 20 nucleotides. If X and Y are too short the oligonucleotide looses its specificity.
- X or Y may include stabilising modifications.
- two or three natural 3' -5' phosphodiester linkages at at least the 3' end of X may be modified in an attempt to protect the oligonucleotide from attack by 3'-exonucieases.
- 3'-5' phosphodiester linkage may be replaced by phosphorothiat-e linkages such as thiophosphodiester linkages.
- the 2'-R substituent is a non-nucleophylic group which is isoteric and isopolar with the replaced -OH group.
- the substituent has both H-bond donor and acceptor abilities.
- a 2'-COOH substituent, which can chelate with Mg 2+ is advantageous because it is known to be important for Mg 2+ binding.
- modifications according to the invention which involve the 2'-R substitution of nucleotides in the catalytic/cleavage region of the oligonucleotide can provide a desirable increase in stability against degradation and can increase catalytic activity due to improved Mg 2+ binding.
- Oligonucleotides according to the invention with diol bridges can ne made by machine more easily and more cheaply than conventional ribozymes.
- the oligonucleotides of the present invention may be used as intermediates for further modification to improve their ease of up- take by the cell (in comparison to unmodified oligonucleotides of the invention and known ribozymes), for example by the attachment of carrier molecules.
- the emoodiments navmg diol bridges are considered to be particularly useful as intermediates for this purpose.
- the oligonucleotides of the present invention are potential antagonists of a wide range of therapeutic targets which involve over-expression of products. By binding to specific targets on mRNA and cleaving the mRNA they can stop translation and hence "switch off" a specific gene. In cases where expression of a product (e.g. an enzyme or a protein) by a gene is causative of an illness or disfunction this could lead to a cure. Alternatively a putative gene as a source of a problem phenomenon could be "switched off” selectively and the tnerapeutic effect observed.
- the oligonucleotides of the present invention are potential anticancer and antiviral agents and could also be used as anti-inflammatory and anti-ulcer drugs.
- oligonucleotides of the present invention suggest that they could be used in nanomolar amounts. This offers a significant improvement over known ribozymes which have to be used in relatively large amounts to compensate for tneir mtracellular degradation by nucleases.
- the oligonucleotides of the invention may achieve true catalytic activity: i.e. they will not be destroyed in the cleavage reaction.
- the invention can also provide novel intermediates which are 2' substituted nucleosides needed to construct the oligonucleotides of the present invention.
- Such reactive intermediates may be protected where appropriate by a removable protecting group.
- the invention can also provide a method which comprises the synthesis of an oligonucleotides according to the invention from building blocks including deoxynucleotides and 2' substituted nucleosides.
- Figure 1 shows the nucleotide sequence of a hammerhead ribozyme.
- Figure 2 shows an example of therapeutic target interaction between the myc oncogene mRNA and an oligonucleotide of the invention of the type described in Example 1.
- Figure 3 shows a synthetic scheme for producing 2' - CF 2 H substituted nucleosides.
- Figure 4 shows a synthetic scheme for producing 2' - COOH substituted nucleosides.
- Figure 5 shows a synthetic scheme for producing the nucleoside 9-(2'-C-difluoromethyl - ⁇ - D arabino - furanosyl) - 6 Ethoxy purine.
- N represents any deoxyribonucleotide recognition sequence specific for the target RNA
- N.N represents a thiophosphodiester linkage replacing a natural
- A is deoxyadenosine
- G is deoxyguanosine
- a is 2' substituted deoxyadenosine according to formula la below
- g is 2' substituted deoxyguanosine according to formula lb below
- R 1 being -H, -C(O)OH or -CH 2 -C(O)OH and W is nucleotide loop sequence Ila.
- N represents any deoxyribonucleotide recognition sequence specific for the target RNA
- N.N represents a thiophosphodiester linkage replacing a natural
- A is deoxyadenosine
- G is deoxyguanosine
- a is 2' substituted deoxyadenosine according to formula la below
- g is 2' substituted deoxyguanosine according to formula lb below in which R is selected from
- R 1 being -H, -C(O)OH or -CH 2 -C(O)OH
- W is nucleotide loop sequence IIb.
- N, N.N, A, C, G, U, a and g are as defined for Example 1 and the diol bridges are connected with phosphodiester or substituted neutral ohosohotriester derivative linkages.
- N, N.N, A, C, G, U, a and g are as defined for Example 1 and the diol bridges are connected with phosphodiester or substituted neutral phosphotriester derivative linkages.
- FIG. 2 A therapeutic target interaction between mRNA and an oligonucleotide of the invention is shown in Figure 2.
- the -myc oncogene mRNA secondary structure is shown from nucleotide 1 to nucleotide 900. Translation starts at nucleotide 421 and the triplet cleavage site is positions 433 to 435 (GUU).
- 3 is a purine or pyrimidine heterocycle, i.e. adenine, cytosme, guanme or uracil which may be protected where appropriate.
- 6 -Ethoxypurme is a synthetic synthon for adenine; we did not convert to an adenosine derivative on the nucleoside level, because the 6-ethoxy group is a suitable base protecting group during oligonucleotide synthesis.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU59741/94A AU5974194A (en) | 1992-12-04 | 1993-12-03 | Oligonucleotides with rna cleavage activity |
EP94905771A EP0672122A1 (en) | 1992-12-04 | 1993-12-03 | Oligonucleotides with rna cleavage activity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929225427A GB9225427D0 (en) | 1992-12-04 | 1992-12-04 | Oligonucleotides with rna cleavage activity |
GB9225427.5 | 1992-12-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1994013789A2 true WO1994013789A2 (en) | 1994-06-23 |
WO1994013789A3 WO1994013789A3 (en) | 1994-08-04 |
Family
ID=10726157
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1993/002486 WO1994013789A2 (en) | 1992-12-04 | 1993-12-03 | Oligonucleotides with rna cleavage activity |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0672122A1 (en) |
AU (1) | AU5974194A (en) |
GB (1) | GB9225427D0 (en) |
WO (1) | WO1994013789A2 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995006764A2 (en) * | 1993-09-03 | 1995-03-09 | Vpi Holdings Ltd. | Oligonucleotides with rna cleavage activity |
WO1995006731A2 (en) * | 1993-09-02 | 1995-03-09 | Ribozyme Pharmaceuticals, Inc. | Non-nucleotide containing enzymatic nucleic acid |
EP0767657A1 (en) * | 1994-06-22 | 1997-04-16 | NeXstar Pharmaceuticals, Inc. | Novel method of preparation of known and novel 2'-modified nucleosides by intramolecular nucleophilic displacement |
WO1997018312A1 (en) * | 1995-11-14 | 1997-05-22 | Vimrx Holdings, Ltd. | Chimeric oligomers having an rna-cleavage activity |
US6610478B1 (en) | 1996-08-16 | 2003-08-26 | Yale University | Phenotypic conversion of cells mediated by external guide sequences |
WO2003093290A2 (en) * | 2002-05-06 | 2003-11-13 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis c virus infection |
US6737236B1 (en) | 1997-01-08 | 2004-05-18 | Proligo, Llc | Bioconjugation of macromolecules |
US7098326B2 (en) | 2002-01-23 | 2006-08-29 | Sigma-Aldrich Co. | Methods for the integrated synthesis and purification of oligonucleotides |
US7427678B2 (en) | 1998-01-08 | 2008-09-23 | Sigma-Aldrich Co. | Method for immobilizing oligonucleotides employing the cycloaddition bioconjugation method |
US7615629B2 (en) | 2002-12-31 | 2009-11-10 | Sigma-Aldrich Co. | Methods and compositions for the tandem synthesis of two or more oligonucleotides on the same solid support |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU730934B2 (en) * | 1993-09-02 | 2001-03-22 | Ribozyme Pharmaceuticals, Inc. | Non-nucleotide containing enzymatic nucleic acid |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991019789A1 (en) * | 1990-06-19 | 1991-12-26 | Commonwealth Scientific And Industrial Research Organisation | Endonucleases |
WO1992007065A1 (en) * | 1990-10-12 | 1992-04-30 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Modified ribozymes |
-
1992
- 1992-12-04 GB GB929225427A patent/GB9225427D0/en active Pending
-
1993
- 1993-12-03 WO PCT/GB1993/002486 patent/WO1994013789A2/en not_active Application Discontinuation
- 1993-12-03 EP EP94905771A patent/EP0672122A1/en not_active Withdrawn
- 1993-12-03 AU AU59741/94A patent/AU5974194A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991019789A1 (en) * | 1990-06-19 | 1991-12-26 | Commonwealth Scientific And Industrial Research Organisation | Endonucleases |
WO1992007065A1 (en) * | 1990-10-12 | 1992-04-30 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Modified ribozymes |
Non-Patent Citations (4)
Title |
---|
CARBOHYDRATE RESEARCH vol. 216 , 22 September 1991 , AMSTERDAM NL pages 257 - 269 MARRIOTT, J. ET AL. 'synthesis of 2'-thioadenosine' * |
J. AM. CHEM. SOC., 115 (18), 8 September 1993 pages 8483 - 8484 BENSELER, F. ET AL 'Hammerhead-like molecules containing non-nucleoside linkers are active RNA catalysts' * |
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA vol. 89, no. 9 , 1 May 1992 , WASHINGTON US pages 3985 - 3989 FU, D.-J. & MCLAUGHLIN, L. 'Importance of specific purine amino and hydroxyl groups for efficient cleavage by a hammerhead ribozyme' * |
TETRAHEDRON LETTERS vol. 45 , 1978 , OXFORD GB pages 4341 - 4244 RANGANATHAN, R. & LARWOOD, D. 'Facile conversion of adenosine into new 2'-substi -tuted-2'-deoxy-arabinofuranosyladenine derivatives: stereospecific synthesis of 2'-azido-2'-deoxy-, 2'-amino-2'-deoxy-, and 2'mercapto--2'-deoxy-beta-D-arabino- furanosyladenines' * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995006731A2 (en) * | 1993-09-02 | 1995-03-09 | Ribozyme Pharmaceuticals, Inc. | Non-nucleotide containing enzymatic nucleic acid |
WO1995006731A3 (en) * | 1993-09-02 | 1995-07-06 | Ribozyme Pharm Inc | Non-nucleotide containing enzymatic nucleic acid |
WO1995006764A2 (en) * | 1993-09-03 | 1995-03-09 | Vpi Holdings Ltd. | Oligonucleotides with rna cleavage activity |
WO1995006764A3 (en) * | 1993-09-03 | 1995-10-19 | Ribonetics Gmbh | Oligonucleotides with rna cleavage activity |
EP0767657A4 (en) * | 1994-06-22 | 1999-01-20 | Nexstar Pharmaceuticals Inc | Novel method of preparation of known and novel 2'-modified nucleosides by intramolecular nucleophilic displacement |
EP0767657A1 (en) * | 1994-06-22 | 1997-04-16 | NeXstar Pharmaceuticals, Inc. | Novel method of preparation of known and novel 2'-modified nucleosides by intramolecular nucleophilic displacement |
US6090932A (en) * | 1994-06-22 | 2000-07-18 | Proligo Llc | Method of preparation of known and novel 2'-modified nucleosides by intramolecular nucleophilic displacement |
WO1997018312A1 (en) * | 1995-11-14 | 1997-05-22 | Vimrx Holdings, Ltd. | Chimeric oligomers having an rna-cleavage activity |
US6610478B1 (en) | 1996-08-16 | 2003-08-26 | Yale University | Phenotypic conversion of cells mediated by external guide sequences |
US6737236B1 (en) | 1997-01-08 | 2004-05-18 | Proligo, Llc | Bioconjugation of macromolecules |
US7427678B2 (en) | 1998-01-08 | 2008-09-23 | Sigma-Aldrich Co. | Method for immobilizing oligonucleotides employing the cycloaddition bioconjugation method |
US7098326B2 (en) | 2002-01-23 | 2006-08-29 | Sigma-Aldrich Co. | Methods for the integrated synthesis and purification of oligonucleotides |
WO2003093290A2 (en) * | 2002-05-06 | 2003-11-13 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis c virus infection |
WO2003093290A3 (en) * | 2002-05-06 | 2004-03-18 | Genelabs Tech Inc | Nucleoside derivatives for treating hepatitis c virus infection |
US7615629B2 (en) | 2002-12-31 | 2009-11-10 | Sigma-Aldrich Co. | Methods and compositions for the tandem synthesis of two or more oligonucleotides on the same solid support |
Also Published As
Publication number | Publication date |
---|---|
AU5974194A (en) | 1994-07-04 |
WO1994013789A3 (en) | 1994-08-04 |
EP0672122A1 (en) | 1995-09-20 |
GB9225427D0 (en) | 1993-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5334711A (en) | Synthetic catalytic oligonucleotide structures | |
Lima et al. | Structural requirements at the catalytic site of the heteroduplex substrate for human RNase H1 catalysis | |
Tuschl et al. | Importance of exocyclic base functional groups of central core guanosines for hammerhead ribozyme activity | |
US5627053A (en) | 2'deoxy-2'-alkylnucleotide containing nucleic acid | |
AU2012304358B2 (en) | Synthesis and uses of nucleic acid compounds with conformationally restricted monomers | |
US5840876A (en) | 2'-O-alkylthioalkyl and 2'-C-alkylthioalkyl-containing nucleic acids | |
DE69732911T2 (en) | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEANING RNA | |
JP6817493B2 (en) | Method for producing single-strand RNA | |
JPH07501527A (en) | Enhanced Triple Helix and Double Helix Forming Using Modified Pyrimidine-Containing Oligomers | |
PT1013661E (en) | 2`-o,4`-c-methylene bicyclonucleosides | |
JPH06501389A (en) | Nuclease-resistant, pyrimidine-modified oligonucleotides to detect and modulate gene expression | |
CA2092002A1 (en) | Modified internucleoside linkages | |
JPH10510433A (en) | Oligonucleotides with high chiral purity phosphorothioate linkages | |
WO1994013789A2 (en) | Oligonucleotides with rna cleavage activity | |
AU665113B2 (en) | Oligoribonucleotide and ribozyme analogs with terminal 3'-3' and/or 5'-5' linkages | |
WO1995006764A2 (en) | Oligonucleotides with rna cleavage activity | |
US7101992B1 (en) | Nucleic acid base pair | |
LEYDIER et al. | 4′-thio-RNA: synthesis of mixed base 4′-thiooligoribonucleotides, nuclease resistance, and base pairing properties with complementary single and double strand | |
US6605708B1 (en) | Building blocks with carbamate internucleoside linkages and oligonucleotides derived therefrom | |
Yu et al. | Studies on the syntheses and biological activities of isonucleosides | |
US5646021A (en) | Finderons and methods of their preparation and use | |
Yang et al. | Synthesis and duplex stabilization of oligonucleotides consisting of isonucleosides | |
Sproat et al. | Novel solid-phase synthesis of branched oligoribonucleotides, including a substrate for the RNA debranching enzyme | |
Lei et al. | Hybrid characteristics of oligonucleotides consisting of isonucleoside 2′, 5′-anhydro-3′-deoxy-3′-(thymin-1-yl)-D-mannitol with different linkage modes | |
CA2078256A1 (en) | Synthesis of sulfide-linked di-or oligonucleotide analogs and incorporation into antisense dna or rna |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
CFP | Corrected version of a pamphlet front page |
Free format text: ABSTRACT REPLACED BY CORRECT ABSTRACT |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994905771 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1994905771 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994905771 Country of ref document: EP |